Vaishali Pharma
Vaishali Pharma
HealthcareKey Fundamentals
MicrocapPharmaceuticalsHealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
4- Promoter holding has decreased over last quarter: -1.07%
- Promoter holding is low: 30.5%
- Earnings include an other income of Rs.3.57 Cr.
- Company has high debtors of 170 days.
Growth Rate
Quarterly Results
| Particulars | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 33.45 | 24.65 | 26.93 | 22.89 |
| Expenses | 32.06 | 23.09 | 27.13 | 21.4 |
| Operating Profit | 1.39 | 1.56 | -0.2 | 1.49 |
| OPM % | 4.16% | 6.33% | -0.74% | 6.51% |
| Other Income | 0.84 | 0.89 | 1.26 | 0.58 |
| Interest | 0.4 | 0.51 | 0.72 | 0.2 |
| Depreciation | 0.17 | 0.13 | 0.16 | 0.14 |
| PBT | 1.66 | 1.81 | 0.18 | 1.73 |
| Tax % | 28.31% | 28.18% | -61.11% | 13.87% |
| Net Profit | 1.19 | 1.32 | 0.41 | 1.55 |
| EPS in Rs | 0.09 | 0.1 | 0.03 | 0.12 |
Profit & Loss
| Particulars | Mar 2026 | TTM |
|---|---|---|
| Sales | 109 | 108 |
| Expenses | 105 | 104 |
| Operating Profit | 4 | 4 |
| OPM % | 3.8% | 3.9% |
| Other Income | 4 | 4 |
| Interest | 2 | 2 |
| Depreciation | 1 | 1 |
| PBT | 5 | 5 |
| Tax % | 25% | — |
| Net Profit | 4 | 4 |
| EPS in Rs | 0.32 | 0.34 |
| Div. Payout % | 0% | — |
Balance Sheet
| Particulars | Mar 2026 |
|---|---|
| Equity Capital | 26 |
| Reserves | 43 |
| Borrowings | 19 |
| Other Liabilities | 35 |
| Total Liabilities | 123 |
| Fixed Assets | 2 |
| CWIP | 0 |
| Investments | 6 |
| Other Assets | 116 |
| Total Assets | 123 |
Cash Flow
| Particulars | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -7 | -4 | 5 | 0 | -9 | 4 | 3 | 2 | 1 | 1 | 1 | -18 |
| Investing | 0 | 2 | 3 | 1 | 1 | 0 | 0 | 0 | -1 | 0 | 1 | 0 |
| Financing | 6 | 2 | -8 | -1 | 8 | -4 | -3 | -2 | 0 | -2 | -1 | 18 |
| Net Cash Flow | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Free Cash Flow | -8 | -5 | 5 | 0 | -10 | 4 | 3 | 2 | 0 | 1 | 1 | -18 |
| CFO/OP | -276 | 1,252 | 842 | 16 | -326 | 212 | 433 | 78 | 31 | 28 | 185 | -3,104 |
Ratios
| Particulars | Mar 2026 |
|---|---|
| Debtor Days | 170 |
| Inventory Days | 13 |
| Days Payable | 81 |
| Cash Conversion Cycle | 102 |
| Working Capital Days | 212 |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vaishali Pharma insights
33 extracted metrics + investor summaries across FY14–FY26.
Documents
Frequently Asked Questions about Vaishali Pharma
What does Vaishali Pharma Ltd do?
Where is Vaishali Pharma Ltd (VAISHALI) listed?
Which sector does Vaishali Pharma Ltd belong to?
What is the market capitalisation of Vaishali Pharma Ltd?
What is the PE ratio of Vaishali Pharma Ltd?
What is the 52-week high and low of Vaishali Pharma Ltd?
What is the Return on Equity (ROE) of Vaishali Pharma Ltd?
Company Information
Incorporated in 1989, Vaishali Pharma Ltd does marketing of pharmaceutical products including active pharmaceutical ingredients[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VAISHALI.md for Vaishali Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.